Amgen's Repatha Improves Plaque Stability In Heart Patients

Amgen Inc AMGN has announced positive data from the HUYGENS Phase 3 study assessing if Repatha (evolocumab) could increase the thickness of the fibrous caps to improve a feature of plaque stability.
The data were presented at the oral presentation at ESC Congress 2021.
Repatha, in addition to optimized statin therapy, in comparison with optimized statin therapy alone, significantly improved features of plaque stability in patients with coronary artery disease (CAD).
The study met its primary endpoint, with Repatha treatment increased fibrous cap thickness by 42.7 um compared to an increase of 21.5 um (75% increase versus 39%) on optimized statin therapy alone.
Repatha also improved all of the study's secondary endpoints, including decreasing the maximum lipid arc by -57.5° versus -31.4°.
No new safety risks were identified. The most common treatment-emergent adverse events were angina pectoris, myalgia, hypertension, diarrhea, fatigue, and cough.
Price Action: AMGN shares are up 1.56% at $224.93 during the market session on the last check Friday.